Ameritas Investment Partners’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.6K | Hold |
9,819
| – | – | ﹤0.01% | 2678 |
|
|
2025
Q4 | $13.9K | Hold |
9,819
| – | – | ﹤0.01% | 2793 |
|
|
2025
Q3 | $16.1K | Hold |
9,819
| – | – | ﹤0.01% | 2768 |
|
|
2025
Q2 | $7.18K | Hold |
9,819
| – | – | ﹤0.01% | 3057 |
|
|
2025
Q1 | $7.92K | Hold |
9,819
| – | – | ﹤0.01% | 2885 |
|
|
2024
Q4 | $13.6K | Hold |
9,819
| – | – | ﹤0.01% | 2805 |
|
|
2024
Q3 | $10.2K | Hold |
9,819
| – | – | ﹤0.01% | 2910 |
|
|
2024
Q2 | $17K | Hold |
9,819
| – | – | ﹤0.01% | 2681 |
|
|
2024
Q1 | $23.5K | Hold |
9,819
| – | – | ﹤0.01% | 2495 |
|
|
2023
Q4 | $32.7K | Hold |
9,819
| – | – | ﹤0.01% | 2367 |
|
|
2023
Q3 | $36.7K | Buy |
9,819
+4,704
| +92% | +$21.7K | ﹤0.01% | 2261 |
|
|
2023
Q2 | $21.8K | Hold |
5,115
| – | – | ﹤0.01% | 2520 |
|
|
2023
Q1 | $35K | Hold |
5,115
| – | – | ﹤0.01% | 2194 |
|
|
2022
Q4 | $47K | Hold |
5,115
| – | – | ﹤0.01% | 2096 |
|
|
2022
Q3 | $49K | Hold |
5,115
| – | – | ﹤0.01% | 1986 |
|
|
2022
Q2 | $37K | Hold |
5,115
| – | – | ﹤0.01% | 2182 |
|
|
2022
Q1 | $66K | Hold |
5,115
| – | – | ﹤0.01% | 1897 |
|
|
2021
Q4 | $82K | Hold |
5,115
| – | – | ﹤0.01% | 1796 |
|
|
2021
Q3 | $82K | Hold |
5,115
| – | – | ﹤0.01% | 1808 |
|
|
2021
Q2 | $71K | Hold |
5,115
| – | – | ﹤0.01% | 1943 |
|
|
2021
Q1 | $75K | Hold |
5,115
| – | – | ﹤0.01% | 1829 |
|
|
2020
Q4 | $89K | Hold |
5,115
| – | – | ﹤0.01% | 1637 |
|
|
2020
Q3 | $94K | Hold |
5,115
| – | – | ﹤0.01% | 1465 |
|
|
2020
Q2 | $91K | Sell |
5,115
-504
| -9% | -$8.53K | ﹤0.01% | 1467 |
|
|
2020
Q1 | $91K | Buy |
5,619
+331
| +6% | +$6.12K | 0.01% | 1327 |
|
|
2019
Q4 | $95K | Hold |
5,288
| – | – | ﹤0.01% | 1542 |
|
|
2019
Q3 | $107K | Hold |
5,288
| – | – | ﹤0.01% | 1425 |
|
|
2019
Q2 | $117K | Buy |
5,288
+1,386
| +36% | +$24.1K | 0.01% | 1404 |
|
|
2019
Q1 | $53K | Hold |
3,902
| – | – | ﹤0.01% | 1857 |
|
|
2018
Q4 | $35K | Hold |
3,902
| – | – | ﹤0.01% | 2004 |
|
|
2018
Q3 | $64K | Buy |
3,902
+535
| +16% | +$9.48K | ﹤0.01% | 1840 |
|
|
2018
Q2 | $47K | Hold |
3,367
| – | – | ﹤0.01% | 2017 |
|
|
2018
Q1 | $37K | Hold |
3,367
| – | – | ﹤0.01% | 2078 |
|
|
2017
Q4 | $30K | Hold |
3,367
| – | – | ﹤0.01% | 2223 |
|
|
2017
Q3 | $48K | Hold |
3,367
| – | – | ﹤0.01% | 1918 |
|
|
2017
Q2 | $48K | Buy |
3,367
+544
| +19% | +$10.5K | ﹤0.01% | 1930 |
|
|
2017
Q1 | $60K | Buy |
+2,823
| New | +$69.4K | ﹤0.01% | 1727 |
|
Other funds holding CHRS
VCM
SB
KKRC
CM
CWG
Ameritas Investment Partners's CHRS Position: Q1 2026 in Review
Ameritas Investment Partners held its Coherus Oncology (CHRS) position steady in Q1 2026 at 9,819 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2678.
Ameritas Investment Partners first reported a position in CHRS in Q1 2017 and has held it in 37 quarters since. The position peaked at $117K in Q2 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.
- Ameritas Investment Partners held 9,819 shares of Coherus Oncology worth $16.6K as of Q1 2026.
- Ameritas Investment Partners left its Coherus Oncology share count unchanged in Q1 2026.
- Coherus Oncology made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2678 holding.
- Ameritas Investment Partners first reported a position in Coherus Oncology in Q1 2017 and has held it in 37 quarters since.
- Ameritas Investment Partners's Coherus Oncology position peaked at $117K in Q2 2019.
- 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.
Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.